BLA 761263 · Genentech INC
Lunsumio Velo
Mosunetuzumab-Axgb · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Dec 22, 2022: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 22, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
56
5 Phase 3, 29 recruiting
FAERS reports
1,107
950 serious, 156 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 and 2.4) and Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME See full prescribing information for complete boxed warning. Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity. ( 2.1 , 2.4 , 5.1 )
What it is approved for
From the label in effect Jun 29, 2026.
LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) 1.1 Follicular Lymphoma LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Mosunetuzumab-axgb is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and some healthy B-lineage cells. In vitro, mosunetuzumab-axgb activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2025 Supplement 6 · Efficacy OrphanLetterLabelMedication Guide
- Nov 22, 2024 Supplement 5 · Efficacy OrphanLabelLetter
- Dec 22, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
4 products under this application
- LUNSUMIO VELO · MOSUNETUZUMAB-AXGB 5MG/0.5ML · INJECTABLE, INJECTION · Prescription
- LUNSUMIO · MOSUNETUZUMAB-AXGB 1MG/ML · INJECTABLE, INJECTION · Prescription
- LUNSUMIO VELO · MOSUNETUZUMAB-AXGB 45MG/ML · INJECTABLE, INJECTION · Prescription
- LUNSUMIO · MOSUNETUZUMAB-AXGB 30MG/30ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mosunetuzumab" as an intervention, any sponsor and status, largest first.
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Pivotal-lookingActive, not recruiting
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT06284122 · 790 participants (planned) · Start Jun 7, 2024 · Primary completion Nov 2028
Drug: Mosunetuzumab; Lenalidomide and 9 more · For: Follicular Lymphoma
Sites: Graz, Austria; Krems, Austria; Leoben, Austria · 111 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT02500407 · 713 participants · Start Sep 15, 2015 · Primary completion May 21, 2024
Drug: BTCT4465A (Mosunetuzumab) IV; Atezolizumab and 1 more · For: Lymphocytic Leukemia, Chronic; Lymphoma, Non Hodgkin
Sites: La Jolla, California; Santa Barbara, California; Denver, Colorado · 35 sites in all
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06337318 · 600 participants (planned) · Start Oct 23, 2024 · Primary completion Mar 31, 2032
Drug: Mosunetuzumab; Rituximab and 1 more · For: Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 289 sites in all
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04712097 · 478 participants · Start Oct 27, 2021 · Primary completion Jun 3, 2026
Drug: Mosunetuzumab; Lenalidomide and 2 more · For: Relapsed or Refractory Follicular Lymphoma
Sites: Duarte, California; Atlanta, Georgia; Fort Wayne, Indiana · 111 sites in all
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06090539 · 460 participants (planned) · Start Dec 29, 2023 · Primary completion Oct 28, 2027
Drug: BMS-986458; Rituximab and 4 more · For: Relapsed/Refractory Non-Hodgkin Lymphoma
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 76 sites in all
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03671018 · 422 participants (planned) · Start Sep 25, 2018 · Primary completion Jan 30, 2024
Drug: Mosunetuzumab (IV); Mosunetuzumab (SC) and 3 more · For: B-cell Non-Hodgkin Lymphoma
Sites: Birmingham, Alabama; Duarte, California; Aurora, Colorado · 29 sites in all
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05633615 · 396 participants (planned) · Start Jun 12, 2023 · Primary completion Jun 30, 2030
Drug: Axicabtagene Ciloleucel; Cyclophosphamide and 5 more · For: Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma and 4 more
Sites: Tucson, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 95 sites in all
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05091424 · 332 participants (planned) · Start Mar 7, 2022 · Primary completion Feb 10, 2031
Drug: Mosunetuzumab; Tocilizumab and 2 more · For: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sites: Rochester, Minnesota; New York, New York; Columbus, Ohio · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome299
- disease progression134
- neutropenia96
- off label use77
- pyrexia72
- covid-1969
- death52
- pneumonia51
- malignant neoplasm progression46
- rash44
- covid-19 pneumonia41
- thrombocytopenia34
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 16 |
| 2021 | 52 |
| 2022 | 83 |
| 2023 | 335 |
| 2024 | 104 |
| 2025 | 195 |
| 2026 | 313 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lunsumio (Mosunetuzumab-Axgb)
2024 spending
$213K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$579.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $212,983 |
Part B: Lunsumio (Mosunetuzumab-Axgb) · HCPCS J9350
2024 spending
$25.6M
Beneficiaries
210
1,350 claims
Per beneficiary
$121,760
2024 ASP limit $632.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $11,542,465 |
| 2024 | $25,569,692 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Budde LE, Zhang H, Kim WS, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, et al. · Lancet Oncol 2022 · Clinical Trial, Phase II, Multicenter Study
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, et al. · Nat Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ࣙ2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, et al. · Blood 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.
Shen J, Zhang J, Zhu Z, et al. · Front Oncol 2025 · Systematic Review
- Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Bartlett NL, Sehn LH, Assouline S, et al. · Am J Hematol 2026 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Roche (Genentech) · Also marketed as Lunsumio
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.